Intravesical therapy for superficial bladder cancer: A systematic review of randomised trials and meta-analyses

Cancer Treatment Reviews

Volumn 36, Issue 3, 2010, Pages 195-205

  Shelley, Mike D ^a   Mason, Malcolm D ^b   Kynaston, Howard ^c  

^a Velindre NHS Trust   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Intravesical therapy; Meta analyses; Randomised trials; Superficial bladder cancer; Systematic review

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; BROPIRIMINE; DOXORUBICIN; EPIRUBICIN; ETOGLUCID; GEMCITABINE; INTERFERON; INTERLEUKIN 2; ISONIAZID; KEYHOLE LIMPET HEMOCYANIN; MITOMYCIN C; MITOXANTRONE; OFLOXACIN; PEPLEOMYCIN; PIRARUBICIN; PLACEBO; PYRIDOXINE; TEGAFUR; TENIPOSIDE; THIOTEPA;

ANTIBIOTIC PROPHYLAXIS; BLADDER CANCER; CARCINOMA IN SITU; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYSTITIS; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; HEMATURIA; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SUPERFICIAL BLADDER CANCER; SYSTEMATIC REVIEW; TRANSURETHRAL RESECTION; TUMOR GROWTH; TUMOR RECURRENCE; URINARY FREQUENCY;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; BCG VACCINE; COMBINED MODALITY THERAPY; EPIRUBICIN; HUMANS; IMMUNOTHERAPY; META-ANALYSIS AS TOPIC; MITOMYCIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URINARY BLADDER NEOPLASMS;

EID: 77951207009     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.12.005     Document Type: Review

References (73)

1. Parkin D. The global burden of urinary bladder cancer. Scand J Urol Nephrol 2008, 218(Suppl.):12-20.
2. Morales A., Eidinger D., Bruce C. Intracavity bacillus Calmette-Guerin in the treatment of superficial bladder cancer. J Urol 1976, 116:180-183.
3. Bohle A., Jocham D., Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003, 169(1):90-955.
4. Sylvester R.J., van der Meijden A.P., Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002, 168(5):1964-1970.
5. Huncharek M., Geschwind J.F., Witherspoon B., McGarry R., Adcock D. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol 2000, 53(7):676-680.
6. Pawinski A., Sylvester R., Bouffioux C., Kurth K.H., Parmar M., Bijnens L. A combined analysis of EORTC/MRC randomized clinical trials for the prophylactic treatment of TaT1 bladder cancer. Eortc Genito-Urinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on superficial bladder cancer. Acta Urologica Belgica 1996, 64(2):27.
7. Shelley M.D., Court J., Burgon K., et al. Meta-analysis of intravesical therapy for superficial bladder cancer: superiority of bacillus Calmette-Guerin may be confined to high risk patients. Br J Cancer 2001, 85:53.
8. Han R.F., Pan J.G. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006, 67(6):1216-1223.
9. Martinez-Pineiro J., Flores A.N., Isorna S., et al. Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27mg in superficial bladder cancer. BJU Int 2002, 89(7):671-680.
10. Martinez-Pineiro J., Martinez-Pineiro L., Solsona E., et al. Comparison of a standard BCG dose (81mg) versus a three-fold reduced dose (27mg) in high risk superficial bladder cancer (T1G3, Tis). A CUETO prospective randomised study 95012. Eur Urol 2003, 2(Suppl. 1):190.
11. Bohle A. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27mg) versus very low-dose bacillus Calmette-Guerin (13.5mg) versus mitomycin C. Int Braz J Urol 2008, 34(1):117-118.
12. Badalament R.A., Herr H.W., Wong G.Y., et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J Clin Oncol 1987, 5(3):441-449.
13. Hudson M.A., Ratliff T.L., Gillen D.P., Haaff E.O., Dresner S.M., Catalona W.J. Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial. J Urol 1987, 138(2):295-298.
14. Akaza H., Hinotsu S., Aso Y., Kakizoe T., Koiso K. Bacillus Calmette-Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder: four-year results. Cancer 1995, 75(2):552-559.
15. Lamm D.L., Blumenstein B.A., Crawford E.D., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000, 163(4):1124-1129.
16. Palou J., Laguna P., Millan-Rodriguez F., Hall R., Salvador-Bayarri J., Vicente-Rodriguez J. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J Urol 2001, 165(5):1488-1491.
17. Pan J., Zhou X., Han R., Chen Z. A meta-analysis of randomized trials of maintenance bacillus Calmette-Guerin instillation efficacy against recurrence of T1G3 bladder tumor. Front Med China 2008, 2(3):259-263.
18. van der Meijden A.P., Sylvester R., Oosterlinck W., Hoeltl W., Bono A.V. Maintenance bacillus Calmette-Guerin for TaT1 bladder tumours is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003, 44:429-434.
19. Lamm D.L., DeHaven J.I., Shriver J., Sarosdy M.F. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer. J Urol 1991, 145(4):738-740.
20. Luftenegger W., Ackermann D.K., Futterlieb A., et al. Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors. J Urol 1996, 155(2):483-487.
21. Rintala E., Jauhiainen K., Alfthan O., et al. Intravesical chemotherapy (Mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer. Eur Urol 1991, 20:19-25.
22. Lamm D.L., Blumenstein B.A., Crawford E.D., et al. Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. Urol Oncol: Semin Original Invest 1995, 1(3):119-126.
23. Krege S., Giani A., Meyer G.R., Otto T., Rubben H. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics. J Urol 1996, 156(3):962-966.
24. Witjes W.P.J., Witjes A., Oosterhof G.O., Debruyne F.M.J. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Semin Urol Oncol 1996, 1:10-16.
25. Witjes J.A., van der Meijden A.P., Collette L., et al. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology 1998, 52(3):403-410.
26. Malmstrom P.U., Wijkstrom H., Lundholm C., Wester K., Busch C., Norlen B.J. 5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 1999, 161(4):1124-1127.
27. Mangiarotti B., Trinchieri A., Del Nero A., Montanari E. A randomized prospective study of intravesical prophylaxis in non-muscle invasive bladder cancer at intermediate risk of recurrence. Mitomycin chemotherapy vs. BCG immunotherapy. Archivio Italiano di Urologia e Andrologia 2008, 80(4):167-171.
28. Ojea A., Nogueira J.L., Solsona E., et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27mg) versus very low-dose bacillus Calmette-Guerin (13.5mg) versus mitomycin C. Eur Urol 2007, 52(5):1398-1406.
29. Sekine H., Ohya K., Kojima S., IIgarashi K., Fukui I. Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder. Int J Urol 2000, 8(9):483-486.
30. Shelley M.D., Wilt T.J., Court J., Coles B., Kynaston H., Mason M.D. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004, 93(4):485-490.
31. Malmstrom P.-U., Sylvester R.J., Crawford D.E., et al. An individual patient data meta-analysis of the long term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle invasive bladder cancer. Eur Urol 2009, 56:247-256.
32. Friedrich M.G., Pichlmeier U., Schwaibold H., Conrad S., Huland H. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 2007, 52(4):1123-1130.
33. Bohle A., Bock P.R. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urol 2004, 63(4):682-686.
34. Di Stasi S.M., Giannantoni A., Giuriola A., et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 2006, 7:43-51.
35. Sylvester R.J., van der Meijden A.P., Witjes J.A., et al. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005, 174(1):86-91.
36. Rintala E., Jauhiainen K., Kaasinen E., Nurmi M., Alfthan O. Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder Group. J Urol 1996, 156(1):56-59.
37. Gelabert-mas A., Toro O., Schwaibold H., Conrad S., Huland H. A prospective and randomised study of recurrence and progression of superficial bladder cancer treated with mitomycin c alone versus alternating mitomycin c and BCG therapy. Archivos Espanoles de Urologia 1993, 46:397-482.
38. Kaasinen E., Hans W., Malmstrom P.U., et al. Alternating mitomycin c, BCG instillations versus BCG alone in the treatment of carcinoma in situ of the urinary bladder. A Nordic study. Eur Urol Suppl 2002, 1:101.
39. Witjes J.A., Caris C.T., Mungan N., Debruyne F.M., Witjes W.P. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. J Urol 1998, 5:1668-1671.
40. Solsona E., Gonzalez M., Ferandez J.M., Unda M., Bernuy C., Pertusa C. Random trial comparing intravesical chemotherapy with MMC-BCG vs intravesical BCG in patients with intermediate-high risk superficial bladder cancer. Efficacy evaluation of CUETO trial no 93008. Eur Urol 2002, 1(1):101.
41. Kaasinen E., Rintala E., Pere A.K., et al. Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma. J Urol 2000, 164(1):47-52.
42. Khanna O., Cottone R., Son D.L., et al. Superficial bladder cancer treated by intravesical bacillus Calmette-Guerin or Adriamycin: multicenter study interim report. Urology 1997, 15(6):520-528.
43. Lamm D.L., Blumenstein B.A., Crawford E.D., et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. New Engl J Med 1991, 17:1205-1209.
44. Martinez-Pineiro J., Jimenez Leon A.J., Martinez-Pineiro L., et al. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol 1990, 143(3):502-506.
45. Hinotsu S., Akaza H., Asaka S., et al. Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study. Urology 2006, 3:545-549.
46. Cheng C.W., Chan S.F.P., Chan L.W., et al. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer. Int J Urol 2005, 12(5):449-455.
47. de Reijke T.M., Kurth K.H., Sylvester R.J., et al. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906). J Urol 2005, 174(3):405-409.
48. Ali-El-Dein B., Nabeeh B.A., Ismail E.H., Ghoneim M.A. Sequential bacillus Calmette-Guerin and epirubicin versus bacillus Calmette-Guerin alone for superficial bladder tumors: a randomized prospective study. J Urol 1999, 162(2):339-342.
49. van der Meijden A.P., Brausi M., Zambon V., et al. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. J Urol 2001, 166(2):476-481.
50. Bilen C., Ozen H., Aki F.T., Aygun C., Ekici S., Kendi S. Clinical experience with BCG alone versus BCG plus epirubicin. Int J Urol 2000, 7:206-209.
51. Brosman S. Experience with bacillus Calmette-Guerin in patients with superficial bladder cancer. J Urol 1992, 128:27-30.
52. Rischmann P., Colombel M., Malavaud B., Chopin D. Prophylactic ofloxacine to improve tolerance of BCG intravesical instillations: a randomised prospective, double-blind, placebo-controlled, multicentre study in patients with mid to high risk superficial bladder tumours. Eur Urol 2005, 4(Suppl. 3):219.
53. Witjes W.P., Konig M., Boeminghaus F.P., et al. Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group. Eur Urol 1999, 36(6):576-581.
54. Jimenez-Cruz J.F., Vera-Donoso C.D., Witherspoon B., et al. Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guerin and interferon-alpha. Urology 1997, 50(4):529-535.
55. Kalble T., Mohring K., Ikinger U., Riedasch G., Staehler G. Intravesical prevention of recurrence of superficial urinary bladder cancer with BCG and KLH. A prospective randomized study. Urologe 1991, 30(2):118-121.
56. Bercovich E, Deriu M, Manferrari F, Irianni G. BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder. Archivio Italiano di Urologia, Andrologia 1995;67(4):257-60.
57. Ao T., Uchida T., Muramoto M., et al. Postoperative intravesical pirarubicin plus bacillus Calmette-Guerin with or without interleukin 2 instillation therapy for superficial bladder cancer. Nishinihon J Urol 1996, 58(5):538-541.
58. Scaldazza V. Mitomycin C 30mg for 12 months versus mitomycin C 40mg for 6 months in the prophylaxis of superficial bladder carcinoma G1-2. Minerva Urol Nephrol 1996, 48:203-206.
59. Tolley D.A., Parmar M.K., Grigor K.M., et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 1996, 155(4):1233-1238.
60. Newling D.W.W., Kleinjan J.H. A prospective, randomised, multicenter, phase III clinical trial of the effect of different initial therapy regimes and maintenance prophylaxis in superficial bladder cancer, using mitomycin C. Br J Urol 1997, 80(Suppl. 2):31.
61. Schwaibold H., Pichlmeier U., Klingenberger H.J., Huland H. Long-term follow-up of cytostatic intravesical instillation in patients with superficial bladder carcinoma. Is short-term, intensive instillation better than maintenance therapy?. Eur Urol 1997, 31(2):153-159.
62. Heney N.M., Koontz W.W., Barton B., et al. Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study. J Urol 1988, 140(6):1390-1393.
63. Malmstrom P.U. A randomized comparative dose-ranging study of interferon and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder. BJU Int 2002, 89(7):681-686.
64. Tsushima T., Nasu Y., Abeki N., et al. Prophylactic intravesical instillation therapy in patients with superficial bladder cancer. Results of a randomized prospective study. Jpn J Urol 1992, 83(8):1314-1321.
65. Akaza H.K., Koiso K., Kotake T., et al. Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese Urological Cancer Research Group for Adriamycin. Cancer Chemother Pharmacol 1992, 30(Suppl.):S15-S20.
66. Faiola V, Montella L, Addeo R, et al. Intravesical gemicitabine versus mitomycin for recurrent superficial bladder tumour (stages pTA and pT1): a randomised prospective study. Eur J Cancer 2008;Suppl. 6:123-26.
67. Au J.L.S., Badalament R.A., Wientjes M.G., et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 2001, 93(8):597-604.
68. Colombo R., Da Pozzo L.F., Salonia A., et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 2003, 21(23):4270-4276.
69. Di Stasi S.M., Giannantoni A., Stephen R.L., et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 2003, 170(3):777-782.
70. Oosterlinck W., Kurth K.H., Schroder F., Bultinck J., Hammond B., Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993, 149(4):749-752.
71. Gudjonsson S., Adell L., Merdasa F., et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol 2009, 55:773-780.
72. Bohle A., Lehy H., Frei C. Single postoperative instillation of gemcitabine in patients with non-muscle invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo controlled, phase III multicentre study. Eur Urol 2009, 56:495-503.
73. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004;171(6 Pt 1):2186-90.